) is re-entering the weight loss drug market through a new partnership with China's Eccogene. The deal provides AstraZeneca with global rights, excluding China, to develop and commercialize Eccogene's oral GLP-1 candidate for obesity management.
Under the terms, AstraZeneca will pay Eccogene $185 million upfront to license the drug, coming after AstraZeneca halted the development of two previous obesity medications this year due to disappointing trial results.What to eat for breakfast, lunch, dinner, and snacks to gain muscle or lose fat, according to a professional bodybuilding coach
For body recomposition, the amount of calories you eat is key. Here's how to adjust your meals to either gain muscle or lose fat.Rated lowest margin fees by StockBrokers.com. Borrow against your securities at low cost. Rates subject to change. Your capital is at risk.EDMONTON — Alberta is planning to dismantle its provincewide health provider and may sell off its publicly owned continuing-care facilities, say leaked cabinet briefing documents released by the Opposition NDP.
Woman Goes into Hospital for Colon Surgery, Wakes Up to Hysterectomy After Doctors Found Tumor 'Cemented to Uterus' Devlynn Cyr, 38, thought she was having colon surgery but woke up to learn she had undergone a hysterectomy due to discovery of stage 3 cancerDiscover a world of exciting games, from heart-pumping action to brain-teasing puzzles. Get the latest versions of the top games in 2023.One specific time is better for our mental health, according to data.
ایران آخرین اخبار, ایران سرفصلها
Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.
منبع: YahooFinanceCA - 🏆 47. / 63 ادامه مطلب »